Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial

@article{Ainsworth2000PumactantAP,
  title={Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial},
  author={Sb Ainsworth and M W Beresford and D. W. A. Milligan and Nj Shaw and Jns Matthews and AC Fenton and M. W. Platt},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={1387-1392}
}
BACKGROUND Exogenous surfactant preparations vary in their constitution and biophysical properties. Synthetic and animal-derived preparations lower the rate of death compared with controls. No significant differences in mortality or important long-term clinical outcomes have been shown between them in randomised trials. We did a randomised controlled trial to compare pumactant, a synthetic surfactant, with poractant alfa, an animal-derived surfactant, both of which are widely used in the UK… 
Complications among premature neonates treated with beractant and poractant alfa
TLDR
In this study, infants who received poractant had shorter duration of intubation than infants treated with beractant, without any difference in the duration of oxygen therapy or hospitalization.
Is there a Difference in Surfactant Treatment of Respiratory Distress Syndrome in Premature Neonates? A Review
TLDR
New surfactant administration strategies are described, complimenting new respiratory support strategies, designed to minimize invasive mechanical ventilation and decrease the frequency of chronic lung disease.
An observational study of surfactant treatment in infants of 23–30 weeks' gestation: comparison of prophylaxis and early rescue
  • G. Bevilacqua, S. Parmigiani
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2003
TLDR
Not surprisingly, infants treated with prophylactic surfactant had a lower rate of RDS than the infants treated by early rescue, even though they did not need less Surfactant overall.
History of Surfactant from 1980
TLDR
Comparison studies show that multiple doses may be needed if surfactant is used to treat established RDS but early or prophylactic treatment is superior for infants with gestational ages less than 30 weeks, and a meta-analysis of 5 comparative studies suggests that a dose of 200 mg/kg of poractant alfa is associated with lower mortality compared with 100 mg/ kg of beractant.
Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial
TLDR
Poractant alfa may be more beneficial and associated with fewer complications than bovine lipid extract surfactant and larger studies are needed to determine whether observed possible benefits translate in shorter hospital admissions, or other long term benefits and determine whether there is a difference in mortality.
Surfactant Therapy for Respiratory Distress Syndrome in Premature Neonates
  • S. Ainsworth, D. Milligan
  • Medicine
    American journal of respiratory medicine : drugs, devices, and other interventions
  • 2002
TLDR
Despite being an effective therapy for RDS, surfactant has failed to have a significant impact on the incidence of chronic lung disease in survivors and is considered a cost-effective therapy compared with other therapeutic interventions in premature infants.
One-Year Follow-up of Very Preterm Infants Who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials
TLDR
Surviving infants who received lucinactant and other surfactants in the SELECT and STAR trials individually and from analysis using combined data from these 2 trials sought to determine and compare survival and pulmonary and neurodevelopmental outcomes through 1 year corrected age.
Choosing a Right Surfactant for Respiratory Distress Syndrome Treatment
TLDR
Evidence from randomized controlled trials indicates that treatment with natural surfactant results in faster weaning of supplemental oxygen and mean airway pressure, decreased duration of mechanical ventilation, and decreased mortality when compared to synthetic surfactants.
Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?
TLDR
The postnatal airway inflammatory response observed in preterm infants is not altered by the instillation of either surfactant preparation, and ventilation requirements and clinical outcomes were similar between the two groups.
Surfactant administration in premature infants with RDS
TLDR
A reasonable recommendation is to treat the infants as soon as clinical signs of developing respiratory distress appear with an individual dose for each infant, and it is found that early treatment with surfactant replacement- within 6 hours of birth- is more effective, and resulted in a significant reduction of mortality rate.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
TLDR
Treatment with Infasurf resulted in significant improvement in several secondary outcome measures and is suggested that a more effective surfactant is a better option than Exosurf in the prevention of neonatal respiratory distress syndrome.
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.
TLDR
The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours after start of treatment, associated with a trend towards reduced incidence of serious pulmonary and non-pulmonary complications.
A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
TLDR
Although no differences were noted between Survanta- and Exosurf-treated infants regarding the primary outcome of death or chronic lung disease at 28 days of age, the significant improvement in secondary clinical outcomes suggests that SurvantA is more effective than ExosURf Neonatal in the treatment of established RDS.
TWO CONTROLLED TRIALS OF DRY ARTIFICIAL SURFACTANT: EARLY EFFECTS AND LATER OUTCOME IN BABIES WITH SURFACTANT DEFICIENCY
TLDR
There was no significant difference in ventilator pressures or oxygen therapy used nor in neonatal mortality and morbidity in the first 2 years of life between the surfactant-treated and control groups in either trial.
A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.
TLDR
There was no difference between treatment groups in the incidence of death or bronchopulmonary dysplasia or in the duration of hospitalization, assisted ventilation, or supplemental oxygen administration, and a difference in the initial response to treatment as measured by FIO2 and MAP.
Randomized trial of artificial surfactant (ALEC) given at birth to babies from 23 to 34 weeks gestation.
TLDR
This protein free, artificial surfactant should be a useful addition to the therapy of babies under 30 weeks gestation to reduce the severity of their RDS and the incidence of serious complications.
Manual Ventilation with a Few Large Breaths at Birth Compromises the Therapeutic Effect of Subsequent Surfactant Replacement in Immature Lambs
TLDR
It is concluded that a few inflations with volumes that are probably harmless in other circumstances might, when forced into the surfactant-deficient lung immediately at birth, compromise the effect of subsequent Surfactant rescue treatment.
Artificial surfactant and natural surfactant. Comparative study of the effects on premature rabbit lungs.
TLDR
These findings confirm earlier observations that treatment with supplementary surfactant has a beneficial effect on lung mechanics in the premature neonate and the fact that this effect can be obtained not only with natural Surfactant but also with dry artificial surfactants should increase the possibility of clinical application.
Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants.
TLDR
The combined use of corticosteroids and surfactant significantly decreased overall death and death caused by respiratory distress syndrome relative to either treatment alone and improves neonatal outcome.
Comparison of mortality risk: a score for very low birthweight infants
TLDR
The present score is robust, easily obtainable at admission, and permits early randomisation based on mortality risk, which quantifies mortality risk in very low birthweight infants at admission to the neonatal intensive care unit.
...
1
2
3
...